12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Andexanet alfa regulatory update

Portola said FDA granted breakthrough therapy designation for andexanet alfa to reverse the anticoagulant activity of Factor Xa inhibitors. Next half, the company plans to start Phase III testing of the...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >